Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART-PSMA-TGFβRDN in mCRPC
NCT04227275Phase 1Terminated
- Sponsor
- Tceleron Therapeutics, Inc.
- Start
- Nov 2019
- Primary completion
- Nov 2022
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CART-PSMA-TGFβRDN in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Tceleron Therapeutics, Inc. Primary endpoints: Dose Identification of CART-PSMA-TGFβRDN up to 2 years and Safety of CART-PSMA-TGFβRDN up to 2 years. Started Nov 2019; status: terminated.
02
Drugs
CART-PSMA-TGFβRDN
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04227275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04227275.